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HIV-2 is less pathogenic for humans than HIV-1 and
might provide partial cross-protection from HIV-1-
induced pathology. Although both viruses replicate
in theTcells of infectedpatients, onlyHIV-2 replicates
efficiently in dendritic cells (DCs) and activates innate
immune pathways. How HIV is sensed in DC is
unknown. Capsid-mutated HIV-2 revealed that
sensing by the host requires viral cDNA synthesis,
but not nuclear entry or genome integration. The
HIV-1 capsid prevented viral cDNAsensing up to inte-
gration, allowing the virus to escape innate recogni-
tion. In contrast, DCs sensed capsid-mutated HIV-1
and enhanced stimulation of T cells in the absence
of productive infection. Finally, we found that DC
sensing of HIV-1 and HIV-2 required the DNA sensor
cGAS. Thus, the HIV capsid is a determinant of innate
sensing of the viral cDNA by cGAS in dendritic cells.
This pathway might potentially be harnessed to
develop effective vaccines against HIV-1.
INTRODUCTION
The human immune system mounts an immune response
against HIV-1, but this response is not protective in most
individuals. In contrast, the related lentivirus HIV-2, which is
less pathogenic than HIV-1, has been proposed to be controlled
by the immune system (Rowland-Jones and Whittle, 2007).
Remarkably, coinfection with HIV-1 and HIV-2 results in a better
outcome than HIV-1 infection alone, including delayed progres-
sion to AIDS, suggesting that the immune response against
HIV-2 induces cross-reactive protection against HIV-1 pathol-
ogy (Esbjo¨rnsson et al., 2012). A key challenge is thus to under-
stand how the immune system differs in its ability to induce
immune responses against HIV-1 and HIV-2.
Dendritic cells (DCs) play a major role in the induction of
immune responses. Paralleling the pathophysiological differ-1132 Immunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier Inences between the two viruses, DCs differ in their ability to
induce an innate immune response against HIV-1 and HIV-2
(Manel et al., 2010; Manel and Littman, 2011). DCs do not
normally get activated and efficiently infected by HIV-1
(Granelli-Piperno et al., 2004; Manel et al., 2010), whereas
DCs are naturally infected and activated by HIV-2 (Manel
et al., 2010). The absence of DC activation by HIV-1 is in part
a consequence of the poor ability to infect these cells (Manel
et al., 2010), which is imposed by the restriction factor
SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011), an
Aicardi-Goutie`res Syndrome (AGS) susceptibility gene (Rice
et al., 2009). In contrast, HIV-2 encodes the small accessory
protein Vpx, which overcomes the SAMHD1 restriction in
DCs. The Vpx protein is incorporated into the viral particles
and released into the DCs after viral entry where it induces
degradation of SAMHD1. When HIV-1 is complemented with
the Vpx protein, DCs become readily infected (Goujon et al.,
2006). Infected DCs in turn sense the virus and induce a
concomitant innate immune response (Manel et al., 2010). In
this setting, sensing of HIV-1 requires genome integration
and expression of the viral capsid (Manel et al., 2010; Sunseri
et al., 2011) and requires interaction between the newly synthe-
sized viral capsid and the cellular prolyl-isomerase Cyclophilin
A (CypA) (Luban et al., 1993; Manel et al., 2010). However,
whether capsid or another viral component is the actual path-
ogen-associated molecular pattern (PAMP) in DCs is not
known. Intriguingly, DCs do not sense the reverse-transcribed
HIV-1 cDNA or the incoming capsid before viral integration
occurs, even in the presence of Vpx. Whether DCs are compe-
tent for sensing HIV-1 before integration occurs or whether
they lack the sensing machinery remains to be determined.
Here, we focused on HIV-2 sensing by DCs to identify the
mechanism of HIV-1 and HIV-2 sensing and the DC sensor.
We set out to examine the role of the HIV-2 capsid in innate
sensing by perturbing its affinity for CypA. We identify a strik-
ing capsid-mutated HIV-2 that activates DCs while losing its
ability to productively infect the cell. We find that DC activation
by HIV-2 requires the viral cDNA and occurs in the cytosol,
before nuclear entry and integration. We show that DCs can
also sense the HIV-1 cDNA before integration when the analo-
gous mutation is introduced in its capsid and Vpx is present.c.
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Figure 1. Modulation of HIV-2 Capsid Affinity for Cyclophilin A, a
Host Factor Implicated in Innate Sensing by Dendritic Cells
(A) Alignment of the CypA-binding loops of HIV-1 and HIV-2 capsids. H87A88
and P90 in HIV-1 and P86 and P88 in HIV-2 are indicated in bold.
(B) Sequence of the putative HIV-2 affine capsid, HIVac-2 (HIV-2 P86HA
mutation), same region as in (A).
(C) The structure of the HIV-2 capsid N-terminal domain (red, PDB 2WLV) is
aligned on the HIV-1 capsid NTD bound to CypA (respectively blue and gray,
PDB 1AK4).
(D) Magnification of the CypA catalytic site bound to HIV-1 (respectively gray
and blue, PDB 1AK4) or HIV-2 capsids (red, PDB 2WLV). The two residues
H87A88 in HIV-1 capsid position the proline substrate to interact with H125
and R55 in CypA. In HIV-2, P86 induces a distortion in the loop that prevents
these interactions.
(E) The P86HA mutation in HIVac-2 leads to CypA incorporation in viral
particles. Left shows protein expression in virus-producing cells. HIV-1, HIV-2
or HIVac-2 viral proteins were analyzed by immunoblotting against
Gag/Capsid, CypA, and actin. Right shows viral particles that were analyzed
by immunoblotting against Gag/Capsid and CypA.
See also Figure S1.
Immunity
Innate Sensing of HIV by cGAS in Dendritic CellsDCs response to capsid-mutated HIV-1 leads to activation
of CD4+ and CD8+ T cells in the absence of productive
infection, which is reminiscent of the adjuvant activity of live
attenuated vaccines. Finally, we find that the cytosolic DNA
sensor cGAS is essential in human DCs for innate sensing of
HIV-1 and HIV-2.ImmRESULTS
Engineering HIV-2 Capsids of Variable Affinity for CypA
to Modulate Sensing in DCs
In HIV-1, the interaction of capsid with CypA is required for DC
activation (Manel et al., 2010). We reasoned that altering the
capsid-CypA interaction might allow us to gain mechanistic
insight into sensing by DCs; in particular, the natural sensing of
HIV-2. We noticed that two residues in HIV-1 capsid (His87-
Ala88) located in the CypA-binding loop (Yoo et al., 1997), align
to only one residue in HIV-2 capsid (Pro86) (Figure 1A), which
binds less efficiently to CypA (Price et al., 2009). In HIV-1,
His87-Ala88 position the Pro90, the substrate of the isomerizing
activity, into the catalytic site of CypA. Strikingly, in the aligned
capsid of HIV-2, the homologous Pro88 is not positioned
correctly in the catalytic site of CypA (Figures 1C and 1D). This
raised the possibility that introducing His-Ala in place of Pro86
in HIV-2 (Figure 1B) would position Pro88 in the catalytic site
and increase the affinity of HIV-2 capsid for CypA (HIV-2 affinity-
enhanced capsid, HIVac-2), potentially perturbing innate
sensing by DCs.
Expression of HIVac-2 was similar to its WT counterpart, and
the mutation did not alter expression of CypA in virus-producing
cells (Figure 1E). Examination of particles by transmission
electron microscopy showed a typical lentiviral ultrastructure
(data not shown). However, HIVac-2 particles encapsidated 28
times more CypA than HIV-2 WT and 3 times more than HIV-1
(Figure 1E; see also Figure S1A available online). We measured
the binding of recombinant capsid proteins (N-terminal domains)
to recombinant CypA (Figures S1B and S1C). With a coprecipi-
tation assay, HIVac-2 capsid remained better associated to
CypA compared to HIV-2 WT capsid. The association was
inhibited by Cyclosporin A, an inhibitor of the capsid-CypA inter-
action that targets the active site of CypA. Next, microscale
thermopheresis (MST) was used to estimate the dissociation
constant between CypA and the capsids. The affinity of HIV-2
WT capsid to CypA was too low to be determined in this assay,
whereas the affinity of HIVac-2 capsid to CypA was 2.6 mM (Fig-
ure S1D). Thus, HIVac-2 capsid boundCypAwith a higher affinity
than the HIV-2 WT capsid.
DC Sensing of Capsid-Mutated HIV-2 in the Absence of
Productive Infection
We examined the ability of HIV-2 WT and HIVac-2 to infect and
activate DCs. We used a single-round HIV-2 vector that ex-
pressed GFP in DCs after integration to measure infection.
Because innate sensing of HIV-1 with Vpx was independent of
the viral envelope used (Manel et al., 2010), we used VSV-G-
pseudotyped particles. As previously shown, HIV-2 WT was
able to infect and activate DCs (Figure 2A) in a dose-dependent
manner (Figure 2B; Figure S2A). Remarkably HIVac-2 infection
was completely blocked in DCs (Figures 2A and 2B; Figure S2A).
Unexpectedly, the block did not prevent DC sensing of HIVac-2,
and HIVac-2 activated DCs more efficiently than HIV-2 WT (Fig-
ure 2B). Addition of virus-like particles (VLPs) from the macaque
simian immunodeficiency virus (SIV), a close relative of HIV-2,
which provides an increased amount of Vpx and boosts abroga-
tion of SAMHD1 restriction (Hrecka et al., 2011; Laguette et al.,
2011), enhanced activation by HIVac-2, but infection was stillunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier Inc. 1133
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Figure 2. Dendritic Cells Sense HIVac-2 in
the Absence of Infection
(A) GFP and CD86 expression in MDDCs 48 hr
after infection with HIV-2 WT or HIVac-2 encoding
GFP in Nef and pseudotyped with VSV-G in the
presence of SIVmac VLPs.
(B) Dose-response expression of GFP and CD86
as in (A) (n = 7 and means; paired t test; *p < 0.05,
***p < 0.001).
(C) Type I IFN production by MDDCs infected with
VSV-G pseudotyped HIV-2 WT or HIVac-2 or
treated with poly(I:C) (pIC) for 48 hr (n = 7 and
means; paired t test; *p < 0.05, **p < 0.01).
(D) IP-10 production (n = 4 andmeans; paired t test
on log-transformed data; *p < 0.05, **p < 0.01) by
MDDCs infected with VSV-G pseudotyped HIV-2
WT or HIVac-2 in the presence of SIVmac VLPs, or
treated with poly(I:C) (pIC) for 48 hr. Dilution
factors of the input viral inoculum are indicated.
See also Figure S2.
Immunity
Innate Sensing of HIV by cGAS in Dendritic Cellsblocked (Figure S2A). DC activation was characterized by pro-
duction of type I interferon (IFN) (Figure 2C) and the type I IFN
response gene IP-10 (CXCL10) (Figure 2D) by the DCs (Manel
et al., 2010). Neutralizing reagents against type I IFN effectively
inhibited expression of IP-10, while CD86 expression was less
dependent on type I IFN (Figure S2B). However, neutralizing
type I IFN did not rescue the infection by HIVac-2, indicating
an intrinsic effect of the mutation. Thus, mutations of the HIV-2
capsid reveal that DCs are competent for innate sensing in the
absence of productive viral infection.
DC Sensing of HIV-2 Requires Synthesis of the Viral
cDNA But Not Integration
We dissected the early steps of the viral cycle to identify the
determinants of HIV-2 that are sensed in DCs (Figure S3A). To
determine whether the viral genetic material was required for
sensing, we generated HIV-2 and HIVac-2 VLPs in which abun-
dance of the viral genomic RNA was reduced by combining two
previously described deletions that disrupt the encapsidation
signal (DJ) (Griffin et al., 2001; Poeschla et al., 1998). The muta-
tion did not prevent Gag maturation in the particles (Figure S3B)
but reduced viral infectivity (Figure S3C). Despite their residual
infectivity, HIV-2 and HIVac-2 VLPs with reduced RNA encapsi-
dation were not efficient at activating DCs (Figure S3D). Thus,
intact encapsidation of the genomic RNA in the particles is
required for sensing. Next, to determine whether viral DNA
generated after reverse transcription was required for sensing,
we produced particles lacking Vpx that are unable to abrogate
the SAMHD1 restriction (DVpx) and are compromised for reverse
transcription. HIV-2 and HIVac-2 particles lacking Vpx were not
infectious and were unable to activate DCs (Figure S3E). To1134 Immunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier Inc.confirm that a viral cDNA was required
for sensing, we added the reverse tran-
scriptase inhibitor AZT at the time of
infection. AZT prevented infection and
sensing by HIV-2 (Figures 3A and 3B).
Thus, synthesis of a viral cDNA is required
for sensing. We next examined whetherintegration was required for sensing by using Raltegravir, an
inhibitor of integrase. As expected, Raltegravir blocked infection
of HIV-2WT (Figure 3A). However, Raltegravir did not prevent DC
activation by HIV-2 WT and HIVac-2 (Figures 3A and 3B). To
confirm that sensing occurred in the absence of integration, we
inactivated the integrase (IN) by introducing a D116A mutation
in its catalytic site in HIV-2 and HIVac-2 (Figure S3A). D116A-
mutated viral particles displayed a normal profile of mature
capsid protein (Figure S3B). HIV-2 IN D116A and HIVac-2 IN
D116A maintained the ability to activate DCs (Figures 3C and
3D). Thus, DCs sense HIV-2 before integration, and the viral
cDNA is required.
DCs Sense HIV-2 in the Cytosol
Sensing of HIV-2 might occur in the cytosol or in the nucleus. We
measured the relative abundance of the ‘‘Late RT’’ HIV-2 cDNA
product, the ‘‘2LTR circles’’ (a hallmark of nuclear entry of the
viral DNA), and the ‘‘integrated’’ proviral DNA after infection of
DCs (Figure S4A). HIV-2 WT generated all forms of DNA in an
AZT-sensitive manner (Figure 4A). HIVac-2, which activates
DCs in the absence of infection, produced normal amounts of
Late RT viral cDNA, but not a substantial amount of 2LTR circles
or integrated DNA (Figure 4A, red arrows). Treatment of HIV-2
WT with Raltegravir reduced the amount of integrated DNA
and also increased the numbers of 2LTR circles, but this was
not the case for HIVac-2. This indicates that sensing occurs
before the formation of the 2LTR circles, thus presumably in
the cytosol. Next, we determined whether nuclear entry was
required for sensing. We mutated the central polypurine-tract
(cPPT), which is required for nuclear import of the viral cDNA in
dendritic cells (Rivie`re et al., 2010; Zennou et al., 2000)
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Figure 3. Dendritic Cells Sensing of HIV-2 Requires a Viral cDNA but Integration Is Dispensable
(A)GFPandCD86expression inMDDCs infectedwithHIV-2WTorHIVac-2 in theabsenceorpresenceofAZTorRaltegravir (RAL)and in thepresenceofSIVmacVLPs.
(B) Dose-response expression of CD86 as in (A) (n = 4 and means; paired t test; *p < 0.05, **p < 0.01, ‘‘ns’’ stands for not statistically significant).
(C) GFP and CD86 expression in MDDCs infected with HIV-2 WT or HIVac-2 with or without a mutation in the catalytic site of integrase (IN D116A) in the presence
of SIVmac VLPs.
(D) Dose-response expression of CD86 as in (C) (n = 6 and means).
See also Figure S3.
Immunity
Innate Sensing of HIV by cGAS in Dendritic Cells(Figure S4A). The mutation did not modify the Gag maturation
profile of viral particles, incorporation of CypA and Vpx, or effi-
ciency of RT (Figures S4B and S4C). We confirmed that the
cPPT mutation reduced infectivity of HIV-2 in nondividing DCs
(Figure 4B) and the abundance of 2LTR circles (Figure S4C).
Sensing of cPPT-mutated HIVac-2 and HIV-2 was maintained
(Figure 4C). Taken together, these results show that sensing of
viral cDNA occurs in the cytosol.
The HIV-1 Capsid Prevents cDNA Sensing, Escaping
Innate Sensing up to Integration
Unlike HIV-2 or HIVac-2, DCs do not sense the HIV-1 cDNA
before integration (Manel et al., 2010). We hypothesized that in
HIV-1 with Vpx the wild-type (WT) capsid masked the viral
DNA, preventing innate sensing up to integration. To examine
whether the HIV-1 cDNA can stimulate an innate response, we
mutated the CypA-binding loop of HIV-1 capsid to the corre-
sponding sequence from HIVac-2 (Figure 5A). HIVac-1 particles
incorporated more CypA (Figures S5A and S5B), and the
HIVac-1 capsid had a higher affinity for CypA thanWTHIV-1 (Fig-
ures S5C and S5D). Similar to HIVac-2, HIVac-1 retained the abil-
ity to activate DCs and induce IP-10 in the presence of Vpx and
showed a reduced infectivity (Figures 5B–D). Blockade of resid-Immual HIVac-1 integration with Raltegravir did not inhibit innate acti-
vation and IP-10 induction (Figures 5B–5D). Genetic inactivation
of integrase in HIVac-1 also maintained the ability to activate
DCs and induce IP-10 (Figure S5E). Thus, the HIV-1 capsid pre-
vents sensing of the viral cDNA, escaping innate sensing before
integration, but capsid mutations lead to cDNA-dependent
sensing in the cytosol similarly to HIV-2 and HIVac-2.
DCs Exposed to Nonintegrative HIVac Activate T Cells
The ability of HIVac to stimulate the innate immune response
induced by HIV-2 in the absence of productive infection promp-
ted us to test whether HIVac could activate T cells. First, to test
whether DCs activated by HIVac could provide functional costi-
mulatory signals to T cell activation, we examined the polyclonal
proliferation of cocultured naive CD4+ T cells in the presence of
suboptimal concentrations of anti-CD3 antibody (Figure S6A).
DCs were exposed to HIVac-2 particles, leading to DC activation
in the absence of infection (Figure 6A; Figure S6B). In the pres-
ence of a limiting dose of an anti-CD3 antibody, cocultured
primary naive CD4+ T cells proliferated when DCs had been
exposed to HIVac-2 (Figure 6A; Figure S6B). This proliferation
was blocked when DC activation was inhibited by AZT, and it
was increased when sensing of the virus was enhanced byunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier Inc. 1135
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Figure 4. Dendritic Cells Sense HIV-2 Viral cDNA in the Cytosol
(A) Quantification of Late RT, 2LTR circles, and integrated viral cDNA products
24 hr after infection of DCs with HIV-2 WT or HIVac-2 in the presence of
SIVmac VLPs. Cells were treated with AZT or Raltegravir (RAL) (n = 3; repre-
sentative data for 1 donor is shown as means ± SEM of qPCR triplicates). Red
arrows indicate the absence of 2LTR-circles and integrated DNA after infection
by HIVac-2.
(B) GFP and (C) CD86 expression in DCs infected with HIV-2 or HIVac-2 that is
WT or cPPT-mutated in the presence of SIVmac VLPs (n = 4 andmeans; paired
t test; **p < 0.01).
See also Figure S4.
Immunity
Innate Sensing of HIV by cGAS in Dendritic Cellsproviding an additional dose of Vpx with VLPs. Thus, DC activa-
tion by HIVac leads to functional costimulation to CD4+ T cell
activation. Next, we tested whether monocyte-derived DCs
obtained from HIV-1-infected subjects were still competent for
sensing HIVac. We superinfected the DCs with HIV-1 WT or
HIVac-1 in the presence of Vpx and Raltegravir (Figure S6C).
DCs were activated by HIVac-1, but not by the WT virus, and
HIVac-1 sensing was AZT-sensitive (Figure S6D). Thus, DCs
from HIV-1-infected subjects remain competent for innate
activation by the virus. Because noninfectious HIV particles
can provide antigen (Buseyne et al., 2001; Manel et al., 2010),
we examined whether this would increase stimulation of autolo-
gous CD8+ T cells (Figure S6C). DCs exposed to HIVac-1 with
Vpx and Raltegravir increased the proliferation of CD8+ T cells
as compared to HIV-1 WT. (Figures 6B and 6C). This effect
was blocked by AZT treatment in DCs, indicating that it required
innate sensing. Thus, HIVac-1 can stimulate CD8+ T cells from
HIV-1-infected subjects in the absence of integration.
DC Sensing of HIV-1 and HIV-2 Requires cGAS
These results indicate that a cytosolic DNA sensor might be
required for HIV sensing. A large number of candidate DNA sen-
sors have been proposed in recent years in various cell types and
models (Paludan and Bowie, 2013). In the transformed human
cell line THP-1, the sensors cGAS, DDX41, and IFI16 were found
to be required for DNA sensing, leading to type I IFN production
(Sun et al., 2013; Unterholzner et al., 2010; Zhang et al., 2011).
We screened whether these sensors could be implicated in1136 Immunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier InHIV sensing by DCs derived from primary monocytes by using
pooled shRNA. Reducing DDX41 or IFI16 expression did not
inhibit CD86 induction by HIVac-2 (Figures S7A and S7B). In
contrast, inhibition of cGAS expression suppressedCD86 induc-
tion by HIVac-2. We confirmed that the shRNA inhibited cGAS
protein expression by transducing individual shRNA (data not
shown) and selected two shRNA: shRNA #2, which modestly
decreased cGAS expression, and shRNA #4, which efficiently
decreased cGAS expression (Figure 7A). We stimulated
shRNA-transduced DCs with HIV-1, HIV-2, HIVac-2, and the
soluble RNA molecule poly(I:C) as control. cGAS targeting by
RNA interference prevented induction of CD86 by HIV-1,
HIV-2, and HIVac-2, but not sensing of poly(I:C) (Figure 7B).
Titrated infections confirmed that cGAS is required for induction
of CD86 by HIV-1, HIV-2, and HIVac-2 (Figure 7C). cGAS target-
ing by RNA interference also prevented IP-10 production after
stimulation by HIV-2 and HIVac-2 (Figure S7C). Altogether, these
data demonstrate that DC sensing of HIV-1 and HIV-2 is medi-
ated by the DNA sensor cGAS (Figure S7D).
DISCUSSION
We investigated how human DCs sense HIV-1 and HIV-2. The
HIV-1 capsid and its interaction with Cyclophilin A were previ-
ously found to play an essential role in innate sensing of the
virus in DCs with Vpx. However, the actual function of capsid
in innate sensing, the genuine PAMP and the identity of its
sensor were not known. By manipulating the interaction
between the viral capsid and CypA through mutation (HIVac),
we were able to dissociate innate sensing from productive
infection of DCs. By using HIVac as an investigation tool, we
report that DC sensing of HIV-2 requires reverse transcription
of the viral cDNA, but not nuclear entry and integration. In
contrast to HIV-2, we find that DCs cannot sense HIV-1 before
integration because the viral capsid prevents cDNA sensing.
Capsid-mutated HIV-1 revealed that DCs are nonetheless
competent for HIV-1 sensing of the viral cDNA before integra-
tion. Such capsid-mutated particles elicit innate immunity in
DCs and activate T cells in the absence of viral replication.
Finally, we demonstrate that human DCs use the DNA sensor
cGAS to sense the viral cDNA. Thus, our results establish
that, in DCs, the cytosolic viral cDNA is an HIV PAMP and
that the viral capsid dictates whether this cDNA will escape
sensing or will be sensed through cGAS.
Various candidate DNA sensors have been proposed in the
recent years (Paludan and Bowie, 2013) that seem to operate
differently between human and mouse, between cell types and
between DNA stimuli (Abe et al., 2013; Brunette et al., 2012; Cav-
lar et al., 2013; Sun et al., 2013; Unterholzner et al., 2010; Zhang
et al., 2011), and this complexity, which might reflect functional
redundancy, has not been resolved. In human myeloid dendritic
cells, the sensor(s) that are required for sensing cytosolic DNA
are not yet known. One of the DNA sensors, cGAS, synthetizes
cyclic GMP-AMP (cGAMP) upon DNA sensing. cGAMP was
recently detected in DCs infected by HIV-1 in the presence of
Vpx (Gao et al., 2013), but whether cGAS or any other DNA
sensor is actually required for innate sensing in DCs was not
evaluated. By using RNA interference, we demonstrate that
cGAS is essential (nonredundant) for DC sensing of HIV.c.
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Figure 5. Dendritic Cells Are Competent
for Sensing of HIV-1 in the Absence of
Infection but the Wild-Type Viral Capsid
Prevents Innate Sensing of the cDNA up to
Integration
(A) Alignment of the CypA-binding loops of HIV-1
WT, HIV-2 WT, HIVac-2, and HIVac-1 capsids.
(B) GFP and CD86 expression in DCs infected with
HIV-1 WT or HIVac-1. Cells were treated or not
with Raltegravir (RAL) at the time of infection.
SIVmac VLPs were added to provide Vpx.
(C) Dose-response of CD86 expression as in (B)
(n = 5 and means; paired t test; *p < 0.05, ‘‘ns’’
stands for not statistically significant).
(D) IP-10 (CXCL10) production by DCs infected
with HIV-1 WT or HIVac-1 or treated with poly(I:C)
(pIC) for 48 hr, in the absence or the presence of
Vpx-containing SIVmac VLPs or Raltegravir (RAL)
(n = 5 and means ± SEM; paired t test on log
transformed data; **p < 0.01, ***p < 0.001, ‘‘ns’’
stands for not statistically significant).
See also Figure S5.
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Innate Sensing of HIV by cGAS in Dendritic CellsThe demonstration that the WT HIV-1 capsid effectively
prevents sensing of the viral cDNA up to integration provides
an explanation for the absence of innate immune response up
to viral integration in DCs (even in the presence of Vpx) and for
the ability of HIV-1-derived lentiviral vectors to transduce DCs
in the absence of innate sensing against the lentivector itself
(Manel et al., 2010; Satoh and Manel, 2013). Later in the viral
cycle, after integration and productive infection, DC can sense
HIV-1, and this was shown to require expression of newly
synthesized capsid (Manel et al., 2010; Sunseri et al., 2011).
We proposed that sensing in this setting implicated unmasking
of remaining unintegrated cDNA products through interaction
with CypA (Manel and Littman, 2011). The demonstration that
the DNA sensor cGAS is required for HIV-1 sensing argues in
favor of this model.
How does the HIV-1 capsid prevent sensing of the viral cDNA
up to integration? Binding of the HIV-1 capsid to CypA was pre-
viously found to be required for innate sensing of HIV-1 by DCs in
the presence of Vpx (Manel et al., 2010). Furthermore, HIV-1 and
HIV-2 differ in the affinity of their capsid to CypA (Price et al.,
2009), evoking the possibility that the affinity of capsid to CypA
regulates innate sensing. By increasing the capsid affinity for
CypA through mutations, we find that the cDNA gets sensed in
the absence of integration. This suggests that, in addition to
lacking the Vpx protein, HIV-1 has evolved an optimal interaction
of its capsid with CypA that allows cell infection while masking
innate sensing of the cDNA up to integration. In contrast, WT
HIV-2 simultaneously infects the DCs and triggers innate sensingImmunity 39, 1132–1142, Deof its cDNA before integration. This sug-
gests that the HIV-2 capsid accommo-
dates a flexible conformation that can
both unmask the cDNA in the cytosol
leading to sensing and also mediate
infection. HIV-2 seems to achieve this
flexibility through a minimal interaction
of its capsid with CypA. Nonetheless,
HIV-2 is amenable to increased affinityfor CypA through mutation (HIVac-2 capsid), leading to sensing
in the absence of infection, like HIVac-1. The natural balance
between infection and innate sensing in HIV-2 might contribute
to the reduced pathogenicity of this virus, whereas the ability
of HIV-1 to prevent sensing of its cDNA might contribute to its
immune escape.
Three pieces of evidence indicate that the sensing is cytosolic.
First, the amount of 2LTR circles, a hallmark of nuclear import, is
low when DCs respond to HIVac-2 compared to the WT virus.
Second, the cPPT is not required for innate sensing. Even though
the role of the cPPT in nuclear import is incompletely understood
(Dvorin et al., 2002; Rivie`re et al., 2010; Zennou et al., 2000), we
confirmed that in the experimental conditions we used, disrup-
tion of the cPPT reduces the abundance of 2LTR circles but
did not modify the abundance of Late RT cDNA, indicative of in-
hibition before or at nuclear import. Finally, we find that cGAS, a
cytosolic DNA sensor (Sun et al., 2013), is essential for sensing.
DC sensing of HIV cDNA also requires Vpx, which abrogates
the SAMHD1 restriction. SAMHD1 was previously identified as
an AGS-susceptibility gene, a syndrome characterized by
apparent uncontrolled induction of a type I IFN innate response.
SAMHD1 was also found to hydrolyze dNTP in cells, and it is
thought that SAMHD1 removal increases retroviral cDNA syn-
thesis efficiency by replenishment of the dNTP pool (Lahouassa
et al., 2012). Our results establish the first direct link between the
negative regulation of retroviral DNA synthesis by SAMHD1 and
induction of an innate response induced by this DNA. Interest-
ingly, innate sensing of HIV-1 DNAwas reported in cells deficientcember 12, 2013 ª2013 Elsevier Inc. 1137
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Figure 6. Dendritic Cells Exposed to HIVac
Stimulate Adaptive Immunity
(A) Induction of costimulatory functions by HIVac-
2. Expression of CD86 in DCs and proliferation of
primary naive CD4+ T cells as shown by dilution of
a Cell Proliferation Dye (CPD). DCs were initially
infected or not with HIVac-2. AZT was added to
block cDNA synthesis and SIVmac VLPs were
added to increase the dose of Vpx protein.
(B) Proliferation of CD8+ T cells from HIV-1-
infected individuals after coculture with autolo-
gous DCs that were superinfected by HIV-1 WT or
HIVac-1 in the presence of Vpx-containing SIVmac
VLPs and Raltegravir (RAL), with or with AZT (n = 6,
except with AZT n = 4). Cells were gated by
structure, size, and LIVE/DEAD. Representative
plots at day 7 are shown.
(C) Quantification of CD8+ T cell proliferation as in
(B) measured at day 5 and day 7 (n = 6, except with
AZT n = 4). Proliferating cells were gated
by structure, size, and LIVE/DEAD and as
CD4CD8+CPDlo. Staphylococcal Enterotoxin
B (SEB) was used as a positive control of
proliferation.
See also Figure S6.
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Innate Sensing of HIV by cGAS in Dendritic Cellsfor TREX1 (Yan et al., 2010), another AGS-related gene (Rice
et al., 2007). In contrast to sensing in intact human DCs, DNA
sensing in TREX1-deficient cells occurs in the context of the
WT HIV-1 capsid. Furthermore, TREX1 is a proviral factor (Yan
et al., 2009), whereas SAMHD1 is a restriction factor (Hrecka
et al., 2011; Laguette et al., 2011). Overall, while sensing in
DCs and in TREX1-deficient cells converge on DNA sensing
regulated by AGS genes, the viral determinants implicated
appear to be distinct.
While pathogenesis induced by HIV-1 and HIV-2 is associated
with chronic and nonspecific general immune activation, the
virus-specific immune response induced against HIV-2 corre-
lates with its reduced pathogenicity (Rowland-Jones and
Whittle, 2007) and likely contributes its antipathogenic activity
on HIV-1 (Esbjo¨rnsson et al., 2012). Furthermore, immunization
of macaques with a live-attenuated strain of HIV-2 (Putkonen1138 Immunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier Inc.et al., 1995) protects against infection
with a pathogenic SIVmac strain. This
indicates that HIV-2 contains inducers of
anti-HIV and anti-SIV immunity, which
have not been successfully matched in
humans by nonlentiviral vaccine candi-
dates. Given the central role of dendritic
cells in coupling innate sensing to induc-
tion of adaptive immunity, cytosolic
sensing of the HIV-2 cDNA through
cGAS in DCs likely shapes these anti-
HIV-2 immune responses. We find that a
similar DC sensing can be obtained in
the absence of productive infection of
the DCs. Capsid-mutated HIVac-2 and
HIVac-1 can autonomously activate DCs
(with Vpx) in the absence of viral integra-
tion, hence satisfying the definition of aDC adjuvant, and lead to functional costimulation to naive
CD4+ T cells activation and activation of primary CD8+ T cells
from HIV-1-infected subjects, respectively. These effects on
T cells were blocked by inhibition of reverse transcription in
DCs, demonstrating that innate sensing of the viral cDNA in
DCs was required. Although antigen specificity of the prolifer-
ating cells was not examined, previous work showed that DCs
exposed to noninfectious particles comparable to HIVac-1
induce antigen-specific response of CD8+ T cells (Buseyne
et al., 2001; Manel et al., 2010). It will be important to determine
the immunogenicity of HIVac-1 in relevant animal models, with or
without additional antigens. Though no adjuvant is effective to
date for HIV-1 vaccination, the pathway we described provides
several putative advantages. First, HIV-2 is known to induce pro-
tection against HIV-1 pathogenesis, unlike current adjuvants.
Second, the response is specific to HIV, unlike generic adjuvants
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Figure 7. cGAS Is Essential for Dendritic
Cell Sensing of HIV
(A) cGAS protein expression after RNA interfer-
ence, at day 6 after shRNA transduction in
monocytes and differentiation in DCs. One repre-
sentative donor is shown.
(B) Expression of CD86 and GFP in DCs trans-
duced with a control shRNA against LacZ or a
shRNA against cGAS and subsequently infected
with HIV-1, HIV-2, HIVac-2, or stimulated with
poly(I:C) (10 mg/ml). Of note, the shRNA trans-
duction procedure at day 0 includes addition of
Vpx-containing VLPs, which abrogates the
SAMHD1 restriction for HIV-1 infection at day 4.
(C) Dose-response of CD86 in DCs transduced
with shRNA as in (B) and infected with HIV-1,
HIV-2, and HIVac-2 (n = 3).
See also Figure S7.
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Innate Sensing of HIV by cGAS in Dendritic Cellssuch as poly(I:C). Finally, beyond capsid-mutated viruses, our
results suggest that DC-targeted agonists of the cGAS pathway
in the presence of antigen might recapitulate this response. Our
results hence provide a molecular basis for manipulating this
response in order to control or reduce pathogenesis in HIV-1
infected patients and to induce anti-HIV-1 immunity.
Altogether, we have identified a mechanism of HIV-1 and
HIV-2 sensing in DCs, which is tightly regulated by the affinity
of capsid for CypA and which requires the DNA sensor cGAS.
Viral capsid mutations can attenuate the virus and favor trig-
gering of this innate response. Stimulation of this response in
DCs will likely contribute to generating a more effective immune
response against the virus.
EXPERIMENTAL PROCEDURES
Constructs
The HIV-1 WT construct was NL4-3 DvifDvprDvpuDenvDnef encoding GFP in
nef and the HIV-2 WT construct was ROD9 DenfDnef encoding GFP in nef as
previously described (Manel et al., 2010). HIV-1 IN D116A was previously
described (Manel et al., 2010). Mutants HIV-1 V86I-IAP91LPA-M96L
(HIVac-1) and HIV-2 P86HA (HIVac-2), IN D116A, DJ, DVpx, and DcPPT
were generated by overlapping PCR mutagenesis. Combinatory mutations
were generated by standard molecular biology procedures. In the HIVac-1
D116A experiment, a NL4-3 backbone restored for the SL9 class I epitope
was used. Corresponding mutagenized sequences are listed in Table S1.
HIV-2 DJ was generated by combining two previously described packaging
signal deletions (Griffin et al., 2001; Poeschla et al., 1998). CMV-VSVG,
psPAX2, LKO1puro, and pSIV3+ were described elsewhere (Manel et al.,Immunity 39, 1132–1142, De2010). shRNA against IFI16, DDX41, and cGAS
(gene MB21D1) were in the LKO.1-puro vector
(SIGMA) and are listed in Table S2. Human CypA
(gene PPIA) was amplified from cDNA generated
by reverse transcription of total RNA extracted
from PBMCs. In all final constructs, the entire
DNA fragments originating from the PCR and
encompassing the restriction sites used for
cloning were fully verified by sequencing. Full
length human CypA and the NTD of HIV-1
(P1IVQ...TSIL151), HIV-2 WT (P1VQH...TNIL150),
and HIVac-2 (P1VQH...TNIL151) capsids were
amplified by PCR and cloned in a pDONOR vector
(Invitrogen) with the BP Gateway reaction. A TEV
cleavage site (DIPTTENLYFQG) was added to the
N terminus of each protein. CypA was transferredwith the LRGateway reaction into pDEST-His-GST and pDEST-His (pDEST17)
and the capsid NTDs were transferred with the LR Gateway reaction into
pDEST-His-ZZ (Braud et al., 2005). Plasmid DNA was purified with the low
endotoxin HiPure plasmid kit (Invitrogen). Recombinant plasmid DNA did not
induce dendritic cell maturation, and viral-producing cells were washed after
DNA transfection.
Cells
GHOST (GHOST X4R5), 293FT, and HL116 cells were cultured in DMEM, 10%
fetal bovine serum (FBS) (GIBCO), and Penicillin-Streptomycin (GIBCO).
HL116 cells were supplemented with 2% HAT (Invitrogen). Peripheral blood
mononuclear cells were isolated from buffy coats from normal human donors
(approved by the Institut National de la Sante´ et de la Recherche Me´dicale
ethics committee) with Ficoll-Paque PLUS (GE). Human CD14+ cells were
isolated by a positive selection with anti-human CD14 magnetic beads
(Miltenyi). Purity was checked by flow cytometry with an anti-CD14 antibody
(antibodies are listed in Table S3), and purity was superior to 99%. CD14+
and T cells were cultured in RPMI medium, 10% FBS (Biowest), Penicillin-
Streptomicin, Gentamicin (50 mg/ml, GIBCO), and HEPES (GIBCO) in the
presence of recombinant human GM-CSF (Miltenyi) at 10 ng/ml and IL-4
(Miltenyi) at 50 ng/ml. Fresh media was added at day 3, and cells were stimu-
lated or infected at day 4. Human naive CD4+ T cells were sorted by positive
selection with anti-human CD4 magnetic beads (Miltenyi) followed by sorting
on a BD FACSAria IIIu as CD4+CD8bCD27+CD45RO.
Virus Production
Viral particles were produced by transfection of 293FT cells in 6-well plates
with 3 mg DNA and 8 ml TransIT-293 (Mirus Bio) per well; for VSV-G pseudo-
typed SIVmac VLPs, 0.4 mg CMV-VSVG and 2.6 mg pSIV3+; for HIV-1 or
HIV-2 VSV-G pseudotyped viruses, 0.4 mg CMV-VSVG and 2.6 mg HIV
DNA; for shRNA vectors, 0.4 mg CMV-VSV-G, 1 mg psPAX2 and 1.6 mgcember 12, 2013 ª2013 Elsevier Inc. 1139
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Innate Sensing of HIV by cGAS in Dendritic CellsLKO1puro-derived shRNA vector. One day after transfection, media was
removed, cells were washed out once, and fresh media was added. Viral su-
pernatants were harvested 1 day later, filtered at 0.45 mM, aliquoted, and
frozen at 80C. Viral titers were measured by GHOST cell titration as
previously described (Manel et al., 2010). RT activity in viral supernatants
was measured with either a colorimetric kit containing HIV-1 RT as a standard
(Roche) or using the SG-PERT assay (Pizzato et al., 2009) using M-MuLV RT
(Finnzyme) as a standard (1 pg/ml of HIV-1 RT standard corresponds to
185 mU/ml in the SG-PERT assay). Viral supernatants did not induce dendritic
cell activation in the absence infection.
Infections
At day 4 of MDDC differentiation, cells were harvested, counted, and resus-
pended in fresh media at a concentration of 1 million per ml with 5 mg/ml
polybrene, GM-CSF, and IL-4, and 100 ml was aliquoted in round-bottomed
96-well plates. For infection, 50 ml of media or SIVmac VLPs were first added.
One hundredmicrolitres of media or dilutions of viral supernatants were added
next. Azidothymidine (AZT, SIGMA) or Raltegravir (RAL, Euromedex) were
added respectively at 24 mMand 20 mM. For type I IFN neutralization, a cocktail
containing 6 mg/ml recombinant B18R (eBioscience), 1.2 mg/ml monoclonal
anti-IFNa (eBioscience), 1.2 mg/ml monoclonal anti-IFNb (eBioscience),
1.2 mg/ml monoclonal anti-IFNß (Millipore), and 0.6 mg/ml monoclonal anti-
IFNAR2 (Millipore) were added. Forty-eight hours after infection, cell culture
supernatants were harvested and ultraviolet irradiated to inactivate free virus.
Supernatants were subsequently used for a quantitative bioassay for IFNs or
IP-10 quantification. Cell-surface staining of CD86 (eBioscience) was also
performed 48 hr after exposure and analyzed on a BD Accuri C6 or a BD
FACSVerse flow cytometer. Stimulation and DCs activation were positively
controlled by treatment with high molecular weight poly(I:C) (Invivogen).
Targeting of Sensors by RNA Interference
For screening of the sensors, fresh monocytes were cotransduced with a con-
trol empty vector LKO.1-puro or a pool of five shRNA vectors in LKO.1-puro
against IFI16, DDX41, or MB21D1 (SIGMA) as previously described (Manel
et al., 2010; Satoh and Manel, 2013). RNA interference efficiency was
measured by quantitative PCR on day 4. For validation experiments, fresh
monocytes were transduced with an empty vector, a shRNA vector targeting
LacZ, or individual shRNA vectors targeting cGAS. Puromycin was added at
day 2 (2 mg/ml). At day 4, DCs were harvested, counted, resuspended at 0.5
million per ml as described above, seeded at 50,000 cells per well in 96-well
U bottom plate, and infected or stimulated in 200 ml of final volume. Surface
CD86 expression and soluble IP-10 production were measured at day 6.
RNA interference efficiency was measured by quantitative PCR at day 4
and/or immunoblotting at day 6. For CD86 expression, donors for which the
background of CD86 expression was higher than 20% in control samples, or
for which the highest dose of stimulation of control shRNA samples did not
show an induction of at least 20% of CD86-positive cells, were excluded
from the analysis.
Quantitative Bioassay for IFNs
Supernatants were assayed for IFN activity with the HL116 cell line, which
carries a luciferase reporter controlled by the IFN-inducible 6-16 promoter,
as previously described (Uze´ et al., 1994). In brief, the reporter cells were
exposed to cell culture supernatants for 5 hr and assayed for luciferase
activities (Promega), which were then translated to IFN activities by using a
standard curve generated from a serial dilution of human IFNalpha-2a
(ImmunoTools).
IP-10 Protein Quantification
IP-10 concentration was measured on pure or 10-fold dilutions (controls and
HIV infection) or 100-fold dilutions (poly(I:C)) of supernatants from infected
DCs. IP-10 concentration wasmeasured with a Human IP-10 cytometric assay
(BD) according to manufacturer’s protocol. Data was acquired on a BD
FACSVerse (BD) and analyzed in FCAP Array (BD).
HIV-2 Real-Time PCR
Total cellular DNA was harvested with a Nucleospin Tissue kit (Machery-
Nagel). Real-time PCR analysis was adapted from (Brussel and Sonigo,1140 Immunity 39, 1132–1142, December 12, 2013 ª2013 Elsevier In2003) and performed in a Roche LightCycler 480 with Roche 480 SYBR Green
I master reagent in 20 ml final volume per well according to manufacturer spec-
ifications. Each sample was measured in triplicate for all primers. For beta-
globin, primers were bglobin-f CCCTTGGACCCAGAGGTTCT and bglobin-r
CGAGCACTTTCTTGCCATGA. For Late RT, primers were hiv2-30U3-fwd
GAAGGGATGTTTTACCATTTAGTTA and hiv2-psi-rev GTTCCAAGACTTCTC
AGTCTTCTTC. For 2LTR, primers were hiv2-30U3-rev TAACTAAATGGT
AAAACATCCCTTC and hiv2-R-fwd GTTCTCTCCAGCACTAGCAGGTA. For
integrated DNA two rounds of amplification were performed. For the first
round, primers were alu1 GCCTCCCAAAGTGCTGGGATTACAG and hiv2-r
AAGGGTCCTAACAGACCAGGGTCT. For the second round, 1 ml of first-round
reaction was used as template, and primers were hiv2-f2 GCAGGTAG
AGCCTGGGTGTTC and hiv2-r2 CAGGCGGCGACTAGGAGAGAT. Cycling
conditions were 13 95C 50; 353 95C 10’’-50C 20’’-72C 30.’’ Relative
concentrations of Late RT, 2LTR, and integrated viral DNA were calculated
relative to beta-globin (gene HBB) with the DCt method.
Naive T Cell Proliferation Assay
Sorted resting naive CD4+ T cells were stained with a Cell Proliferation Dye
(CPD670, eBioscience). We cocultured 2 3 104 resting T cells with 4 3 103
autologous infected DCs without cytokines in 96-well U bottom plates. Ten-
fold dilutions of anti-CD3 antibody (from 10 pg/ml to 100 ng/ml) or no antibody
were added to replicate wells. At day 4 and day 5 after stimulation, an aliquot of
the cells was fixed and analyzed by flow cytometry on a BD FACSVerse. The
optimal costimulation-dependent concentrations of anti-CD3 were 100 or 10
pg/ml depending on the donor.
Stimulation of CD8+ T Cells from HIV-1-Infected Individuals
Blood samples were collected from HIV-1-positive subjects followed in the
department of clinical immunology of Henri Mondor Hospital, Cre´teil, France
(Table S4). Approval and written informed consent from all subjects were
obtained before study initiation. The study was approved by the ethical com-
mittee CCP IX Ile de France, Henri Mondor Hospital, Cre´teil, France. Fresh
peripheral blood mononuclear cells were isolated from blood patients. Mono-
cytes were isolated by a positive selection with anti-human CD14 magnetic
beads (Miltenyi) and differentiated in DCs for 3 days. The CD14-negative
fraction was cultured in RPMI medium, 10% FBS (Biowest), Penicillin-
Streptomicin, Gentamicin (50 mg/ml, GIBCO), and HEPES (GIBCO) in the pres-
ence recombinant human IL-2 at 50 U/ml and 25 mM AZT or in X-VIVO 20
(LONZA), Penicillin-Streptomicin in the presence of recombinant human IL-2
at 50 U/ml, 10 ng/ml recombinant human IL-7 (Miltenyi), and 25 mM AZT. At
day 3, DCs were superinfected with VSV-G-pseudotyped HIV-1 or HIVac-1
in the presence of SIVmac VLPs, 20 mM Raltegravir, and 25 mM AZT. At day
4, autologous total CD8+ T cells were isolated from the CD14-negative fraction
in culture by a positive selection with anti-human CD8 magnetic beads
(Miltenyi). Sorted CD8+ T cells were stained with a Cell Proliferation Dye
(CPD670, eBioscience). We infected and cocultured 5 3 104 DCs 1 day after
with 105 CD8+ T cells in 250 ml in 96-well round bottom plates. In some wells,
Staphylococcal Enterotoxin B was added at 1 mg/ml (Toxin Technology). At
day 5 of DC differentiation (day 1 of coculture), CD86 and GFP expression
was analyzed in DCs from replicate wells in the absence of T cells. At day 2
of coculture, IL-2 was added in at 20 U/ml and at day 5 of coculture, a half
of the coculture was processed for staining and the other half was kept in fresh
medium with IL-2 at 20 U/ml for 2 more days and processed for staining at day
7 of coculture. Cells were stained with a viability dye (LIVE/DEAD Aqua,
Invitrogen) and with anti-CD8-PE-Cy5.5 and anti-CD4-eFluor-450. Cells
were fixed and analyzed on a BD FACSVerse.
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